The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer: Combination Therapy

Multi-tyrosine kinase inhibitor combined with PD-1 checkpoint inhibitor for advanced or recurrent endometrial cancer not amenable to curative surgery

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer: Combination Therapy?

Lenvatinib is oral multi-targeted tyrosine kinase inhibitor blocking VEGFR1-3, FGFR1-4, PDGFR-alpha, KIT and RET kinases.

Pembrolizumab is intravenous anti-PD-1 humanized monoclonal antibody enhancing T-cell mediated antitumor immunity.

Combination demonstrates synergistic antitumor activity through complementary anti-angiogenic and immune mechanisms.

FDA approval is for advanced endometrial cancer not MSI-H or dMMR with disease progression following prior systemic therapy.

MSI-H or dMMR endometrial cancer responds to single-agent pembrolizumab or dostarlimab as alternative immunotherapy approach.

Symptoms

Hypertension is most common adverse effect requiring proactive antihypertensive management with multiple agents often needed.
Hypothyroidism develops in significant proportion requiring thyroid function monitoring and levothyroxine replacement.
Fatigue, decreased appetite, weight loss affect quality of life requiring nutritional and symptom management.
Diarrhea, nausea, vomiting from lenvatinib require dose modification and supportive care.
Immune-related adverse events including hypothyroidism, hepatitis, pneumonitis, colitis, hypophysitis from pembrolizumab require corticosteroids and discontinuation.

Risk Factors

Pre-existing hypertension requires optimization before initiation and aggressive monitoring during treatment.
History of cardiovascular disease, congestive heart failure, recent myocardial infarction or stroke increase complication risk.
Pre-existing autoimmune disease may worsen with checkpoint inhibition requiring careful risk-benefit assessment.
Hepatic dysfunction requires baseline assessment and dose modification per established criteria.
Bleeding risk with lenvatinib including hemorrhage, fistula formation, gastrointestinal perforation requires careful surveillance.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Advanced or recurrent endometrial cancer beyond first-line platinum chemotherapy warrants systemic therapy evaluation.
  • MSI-H or dMMR testing should be performed on all advanced endometrial cancers to guide therapy selection.
  • Severe hypertensive crisis, hypertensive emergency, posterior reversible encephalopathy syndrome require urgent intervention.
  • Suspected immune-related adverse events including new dyspnea, severe diarrhea, jaundice, neurological symptoms warrant urgent evaluation.
  • Multidisciplinary care including gynecologic oncology, medical oncology, cardiology, endocrinology optimizes complex toxicity management.

Treatment Methods

01
Lenvatinib 20 mg orally daily plus pembrolizumab 200 mg intravenously every 3 weeks represents standard regimen.
02
Aggressive blood pressure management with antihypertensive medications targeting goals less than 140/90 mmHg.
03
Thyroid function monitoring at baseline, weeks 4-6, then every 2-3 months with levothyroxine replacement when needed.
04
Lenvatinib dose modification including holds and reductions for grade 3 toxicities with restart at lower dose.
05
Comprehensive supportive care including hypertension management, hypothyroidism replacement, nutrition support, antidiarrheal therapy, immune-related adverse event protocols, multidisciplinary monitoring optimizes outcomes for this active combination therapy in advanced endometrial cancer.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.